Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

ClinicalTrials.gov · NCT00003653 · Registry updated: 2021-06-23

Condition / research focus: Prostate Cancer
Sponsor: NCIC Clinical Trials Group
Countries with listed sites: Canada
Registry dates and results: Start: 1999-01-05. Completion: 2013-01-10 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bicalutamide (drug)
buserelin (drug)
cyproterone acetate (drug)
flutamide (drug)
goserelin (drug)
leuprolide acetate (drug)
nilutamide (drug)

Where the study takes place — 29 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Tom Baker Cancer Centre
Calgary, Alberta, Canada
Site recruitment: Not reported
Cross Cancer Institute
Edmonton, Alberta, Canada
Site recruitment: Not reported
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
Site recruitment: Not reported
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
Site recruitment: Not reported
Clinical Research Unit at Vancouver Coastal
Vancouver, British Columbia, Canada
Site recruitment: Not reported
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Site recruitment: Not reported
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Site recruitment: Not reported
The Vitalite Health Network - Dr. Leon Richard
Moncton, New Brunswick, Canada
Site recruitment: Not reported
Atlantic Health Sciences Corporation
Saint John, New Brunswick, Canada
Site recruitment: Not reported
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
Site recruitment: Not reported
QEII Health Sciences Center
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
William Osler Health Centre, Brampton Memorial
Brampton, Ontario, Canada
Site recruitment: Not reported
Northeast Cancer Center Health Sciences
Greater Sudbury, Ontario, Canada
Site recruitment: Not reported
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Site recruitment: Not reported
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, Canada
Site recruitment: Not reported
London Regional Cancer Program
London, Ontario, Canada
Site recruitment: Not reported
Credit Valley Hospital
Mississauga, Ontario, Canada
Site recruitment: Not reported
Ottawa Health Research Institute - General Division
Ottawa, Ontario, Canada
Site recruitment: Not reported
Niagara Health System
St. Catharines, Ontario, Canada
Site recruitment: Not reported
Thunder Bay Regional Health Science Centre
Thunder Bay, Ontario, Canada
Site recruitment: Not reported
Odette Cancer Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported
Windsor Regional Cancer Centre
Windsor, Ontario, Canada
Site recruitment: Not reported
CHUM - Hopital Notre-Dame
Montreal, Quebec, Canada
Site recruitment: Not reported
McGill University - Dept. Oncology
Montreal, Quebec, Canada
Site recruitment: Not reported
CHUQ-Pavillon Hotel-Dieu de Quebec
Québec, Quebec, Canada
Site recruitment: Not reported
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Site recruitment: Not reported
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Site recruitment: Not reported
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2

ClinicalTrials.gov · NCT02229734 · Registry updated: 2021-06-04

Condition / research focus: Prostate Cancer
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Countries with listed sites: Canada
Registry dates and results: Start: 2014-12. Completion: 2021-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Radiation (radiation)
Androgen Suppression (drug) — also listed as: LHRH agonist

Where the study takes place — 1 listed sites

London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

ClinicalTrials.gov · NCT04891731 · Registry updated: 2021-05-18

Condition / research focus: Hormone Receptor-positive Breast Cancer
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-05. Completion: 2023-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AI or TAM (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Surgery and ART For Endometrioma

ClinicalTrials.gov · NCT03717870 · Registry updated: 2021-04-29

Condition / research focus: Ovarian Endometrioma; Infertility, Female
Sponsor: Università degli Studi dell'Insubria
Countries with listed sites: No country reported
Registry dates and results: Start: 2023-10. Completion: 2027-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Laparoscopic enucleation of ovarian endometrioma. (procedure)
Prolonged pituitary downregulation (procedure)
Assisted Reproductive Technology (ART) (procedure)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

ClinicalTrials.gov · NCT04840745 · Registry updated: 2021-04-19

Condition / research focus: Early Puberty
Sponsor: Chong Kun Dang Pharmaceutical
Countries with listed sites: South Korea
Registry dates and results: Start: 2021-04. Completion: 2021-11 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CKD-841 A-1 3.75mg (drug) — also listed as: CKD-841
CKD-841 A-1 1.88mg (drug) — also listed as: CKD-841
CKD-841 D 2.92mg (drug) — also listed as: CKD-841
Leuplin Inj. 3.75 mg (drug) — also listed as: Leuplin.Inj

Where the study takes place — 1 listed sites

Severance Hospital
Seoul, Yonsei-ro, Seodaemun-gu 50-1, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

ClinicalTrials.gov · NCT02458716 · Registry updated: 2021-04-08

Condition / research focus: Metastatic Prostate Carcinoma; Metastatic Prostatic Adenocarcinoma; Prostate Carcinoma Metastatic to the Bone
Sponsor: Rutgers, The State University of New Jersey
Countries with listed sites: United States
Registry dates and results: Start: 2015-03-06. Completion: 2020-01-14 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Robotic Assisted Radical Prostatectomy (procedure)
Conventional open retropubic radical prostectomy (procedure)
Laboratory Biomarker Analysis (other)
Quality-of-Life Assessment (other) — also listed as: Quality of Life Assessment
ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide) (drug) — also listed as: Hormone therapy

Where the study takes place — 3 listed sites

City of Hope National Medical Center (COH)
Duarte, California, United States
Site recruitment: Not reported
University of California, Irvine (UCI)
Orange, California, United States
Site recruitment: Not reported
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

ClinicalTrials.gov · NCT03541928 · Registry updated: 2021-04-06

Condition / research focus: High-risk Prostate Cancer; Prostate Cancer
Sponsor: The Methodist Hospital Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2018-08-02. Completion: 2023-07 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HSV-Tk (drug) — also listed as: Gene therapy, AdV-tk gene therapy, Herpes simplex virus thymidine kinase
Valacyclovir (drug) — also listed as: Valtrex
Bicalutamide (drug) — also listed as: Casodex
Leuprolide Acetate (drug) — also listed as: Lupron
Brachytherapy, External beam radiotherapy (radiation) — also listed as: HDR, EBRT
Radical prostatectomy (procedure) — also listed as: Prostatectomy

Where the study takes place — 1 listed sites

Houston Methodist Hospital
Houston, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

ClinicalTrials.gov · NCT01338987 · Registry updated: 2021-03-18

Condition / research focus: Myelodysplastic Syndrome; Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2011-04-19. Completion: 2020-11-19 (may be estimated). Results are posted in this registry.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

First Allogeneic Bone Marrow Transplant (BMT) (procedure)
Leuprolide (drug) — also listed as: Lupron
18F FLT (drug) — also listed as: [18F]fluorothymidine
Cyclophosphamide (drug) — also listed as: Cytoxan
Methotrexate (drug) — also listed as: Trexall
Tacrolimus (drug) — also listed as: Prograf
Total Body Irradiation (radiation)
Busulfan (drug) — also listed as: Busulfex
Fludarabine (drug) — also listed as: Fludara
Second Allogeneic Bone Marrow Transplantation (procedure)

Where the study takes place — 3 listed sites

Childrens National Medical Center
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site recruitment: Not reported
University of Oklahoma
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

ClinicalTrials.gov · NCT04783636 · Registry updated: 2021-03-17

Condition / research focus: Prostate Cancer
Sponsor: Peptron, Inc.
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-03-11. Completion: 2021-07-20 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

leuprorelin acetate 3.75mg (drug) — also listed as: PT105

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer.

ClinicalTrials.gov · NCT03946722 · Registry updated: 2021-02-16

Condition / research focus: Adenomyosis
Sponsor: University College, London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-08-17. Completion: 2024-05-17 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH analogue downregulation (drug)
Participant questionnaire (other)

Where the study takes place — 1 listed sites

University College London Hospital
London, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Psychological Impact of Amenorrhea in Women With Endometriosis

ClinicalTrials.gov · NCT02393482 · Registry updated: 2021-02-04

Condition / research focus: Amenorrhea; Endometriosis; Quality of Life
Sponsor: University of Cagliari
Countries with listed sites: Italy
Registry dates and results: Start: 2021-06. Completion: 2022-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Estroprogestinic therapy (Etinil-estradiol/levonorgestre) (drug)
Gonadotropin-releasing hormone agonist (Leuprorelin acetate) (drug)
Add back therapy 1 (tibolone) (drug)
Add back therapy 2 (calcium carbonate/colecalciferol) (drug)

Where the study takes place — 1 listed sites

University of Cagliari,Obstetrics and Gynecological Department,
Monserrato, Cagliari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

ClinicalTrials.gov · NCT04585932 · Registry updated: 2021-01-20

Condition / research focus: Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Sponsor: M.D. Anderson Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2020-11-24. Completion: 2021-01-08 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Apalutamide (drug) — also listed as: ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927
Degarelix (drug) — also listed as: FE200486, Firmagon
Leuprolide Acetate (drug) — also listed as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
Quality-of-Life Assessment (other) — also listed as: Quality of Life Assessment
Questionnaire Administration (other)
Radiation Therapy (radiation) — also listed as: Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

Where the study takes place — 1 listed sites

M D Anderson Cancer Center
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

ClinicalTrials.gov · NCT04622761 · Registry updated: 2021-01-05

Condition / research focus: Prostate Cancer
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-01-15. Completion: 2026-05-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cabazitaxel (drug) — also listed as: jevtana, XRP6258, RPR116258A

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

ClinicalTrials.gov · NCT03931915 · Registry updated: 2020-12-11

Condition / research focus: Endometriosis
Sponsor: ASKA Pharmaceutical Co., Ltd.
Countries with listed sites: Japan
Registry dates and results: Start: 2019-05-08. Completion: 2020-09-28 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAK-385 (drug) — also listed as: relugolix
Leuprorelin acetate (drug)

Where the study takes place — 41 listed sites

Chubu Rosai Hospital
Aichi, Japan
Site recruitment: Not reported
Meitetsu Hospital
Aichi, Japan
Site recruitment: Not reported
Aiiku Ladies Clinic
Chiba, Japan
Site recruitment: Not reported
Chiba Aoba Municipal Hospital
Chiba, Japan
Site recruitment: Not reported
Tokyo Bay Urayasu Ichikawa Medical Center
Chiba, Japan
Site recruitment: Not reported
Tsujinaka Hospital Kashiwanoha
Chiba, Japan
Site recruitment: Not reported
Fujito Clinic
Hiroshima, Japan
Site recruitment: Not reported
Hashimoto Clinic
Hokkaido, Japan
Site recruitment: Not reported
Tokeidai Memorial Hospital
Hokkaido, Japan
Site recruitment: Not reported
Yoshio Obstetrics Gynecology Hospital
Hokkaido, Japan
Site recruitment: Not reported
Shinsuma Hospital
Hyōgo, Japan
Site recruitment: Not reported
Kagawa Prefectural Central Hospital
Kagawa, Japan
Site recruitment: Not reported
Takamatsu Red Cross Hospital
Kagawa, Japan
Site recruitment: Not reported
Fujisawa City Hospital
Kanagawa, Japan
Site recruitment: Not reported
Rinkan Clinic
Kanagawa, Japan
Site recruitment: Not reported
Second Kawasaki Saiwai Clinic
Kanagawa, Japan
Site recruitment: Not reported
Tawada Ladies Clinic
Kanagawa, Japan
Site recruitment: Not reported
Japanese Red Cross Kumamoto Hospital
Kumamoto, Japan
Site recruitment: Not reported
Kurashiki Medical Clinic
Okayama, Japan
Site recruitment: Not reported
Chayamachi Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Hayakawa Clinic
Osaka, Japan
Site recruitment: Not reported
Minami-Morimachi Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Nomura Clinic Nanba
Osaka, Japan
Site recruitment: Not reported
Rikako Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Tanabe Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Yoshimura Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Dantsuka Clinic
Saitama, Japan
Site recruitment: Not reported
Kashiwazaki Ladies Clinic
Saitama, Japan
Site recruitment: Not reported
Maruyama Memorial General Hospital
Saitama, Japan
Site recruitment: Not reported
Kusatsu General Hospital
Shiga, Japan
Site recruitment: Not reported
Akasaka-Mitsuke Miyazaki Clinic
Tokyo, Japan
Site recruitment: Not reported
Ginza Yoshida Hospital
Tokyo, Japan
Site recruitment: Not reported
Hamada Hospital
Tokyo, Japan
Site recruitment: Not reported
Ikebukuro Metroporitan Clinic
Tokyo, Japan
Site recruitment: Not reported
NS Clinic
Tokyo, Japan
Site recruitment: Not reported
Sei Women's Clinic
Tokyo, Japan
Site recruitment: Not reported
Seijo Kinoshita Hospital
Tokyo, Japan
Site recruitment: Not reported
Shimamura Memorial Hospital
Tokyo, Japan
Site recruitment: Not reported
Toranomon Women's Clinic
Tokyo, Japan
Site recruitment: Not reported
Yokokura Clinic
Tokyo, Japan
Site recruitment: Not reported
Yukawa Women's Clinic
Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

ClinicalTrials.gov · NCT00970203 · Registry updated: 2020-11-03

Condition / research focus: Cancer of Prostate; Cancer of the Prostate; Neoplasms, Prostate; Neoplasms, Prostatic; Prostate Cancer; Prostate Neoplasms; Prostatic Cancer
Sponsor: Roswell Park Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2009-09. Completion: 2019-10-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

androgen ablation (AA) (biological)
DC1 vaccine (biological) — also listed as: alpha dendritic cell 1 vaccine

Where the study takes place — 1 listed sites

University of Pittsburgh Cancer institute
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

ClinicalTrials.gov · NCT00206375 · Registry updated: 2020-10-30

Condition / research focus: Hypothyroidism
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2003-05. Completion: 2011-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone (drug) — also listed as: Humatrope
Growth hormone treatment and puberty (drug) — also listed as: Humatrope

Where the study takes place — 1 listed sites

Baylor college of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

ClinicalTrials.gov · NCT00004054 · Registry updated: 2020-10-22

Condition / research focus: Prostate Cancer
Sponsor: Radiation Therapy Oncology Group
Countries with listed sites: Canada · United States
Registry dates and results: Start: 2000-01. Completion: 2013-11 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bicalutamide (drug) — also listed as: Casodex
estramustine phosphate sodium (drug)
etoposide (drug)
flutamide (drug) — also listed as: Eulexin
paclitaxel (drug)
Luteinizing hormone releasing hormone [LHRH] agonist (drug)
Radiation therapy (radiation)
warfarin (drug) — also listed as: Coumadin

Where the study takes place — 54 listed sites

University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
Site recruitment: Not reported
Foundation for Cancer Research and Education
Phoenix, Arizona, United States
Site recruitment: Not reported
Mount Diablo Medical Center
Concord, California, United States
Site recruitment: Not reported
Sutter Health Western Division Cancer Research Group
Greenbrae, California, United States
Site recruitment: Not reported
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, United States
Site recruitment: Not reported
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado, United States
Site recruitment: Not reported
Baptist Hospital of Miami
Miami, Florida, United States
Site recruitment: Not reported
Lutheran General Cancer Care Center
Park Ridge, Illinois, United States
Site recruitment: Not reported
Methodist Cancer Center at Methodist Hospital
Indianapolis, Indiana, United States
Site recruitment: Not reported
Ball Memorial Hospital Cancer Center
Muncie, Indiana, United States
Site recruitment: Not reported
Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States
Site recruitment: Not reported
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
Site recruitment: Not reported
CCOP - Ochsner
New Orleans, Louisiana, United States
Site recruitment: Not reported
Anne Arundel Oncology Center
Annapolis, Maryland, United States
Site recruitment: Not reported
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, United States
Site recruitment: Not reported
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Site recruitment: Not reported
Marquette General Hospital
Marquette, Michigan, United States
Site recruitment: Not reported
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, United States
Site recruitment: Not reported
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, United States
Site recruitment: Not reported
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Site recruitment: Not reported
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, United States
Site recruitment: Not reported
Monmouth Medical Center
Long Branch, New Jersey, United States
Site recruitment: Not reported
South Jersey Regional Cancer Center
Millville, New Jersey, United States
Site recruitment: Not reported
Atlantic City Medical Center
Pomona, New Jersey, United States
Site recruitment: Not reported
Fox Chase Cancer Center at St. Francis Medical Center
Trenton, New Jersey, United States
Site recruitment: Not reported
CCOP - North Shore University Hospital
Manhasset, New York, United States
Site recruitment: Not reported
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, United States
Site recruitment: Not reported
Akron General Medical Center
Akron, Ohio, United States
Site recruitment: Not reported
Akron City Hospital
Akron, Ohio, United States
Site recruitment: Not reported
CCOP - Columbus
Columbus, Ohio, United States
Site recruitment: Not reported
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported
CCOP - Dayton
Dayton, Ohio, United States
Site recruitment: Not reported
CCOP - Toledo Community Hospital
Toledo, Ohio, United States
Site recruitment: Not reported
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
Allentown, Pennsylvania, United States
Site recruitment: Not reported
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, United States
Site recruitment: Not reported
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, United States
Site recruitment: Not reported
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
CCOP - MainLine Health
Wynnewood, Pennsylvania, United States
Site recruitment: Not reported
Wellspan Health - York Cancer Center
York, Pennsylvania, United States
Site recruitment: Not reported
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
Site recruitment: Not reported
LDS Hospital
Salt Lake City, Utah, United States
Site recruitment: Not reported
Dixie Regional Medical Center
St. George, Utah, United States
Site recruitment: Not reported
University Cancer Center at University of Washington Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, United States
Site recruitment: Not reported
St. Vincent Hospital
Green Bay, Wisconsin, United States
Site recruitment: Not reported
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, United States
Site recruitment: Not reported
St. Luke's Medical Center
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
All Saints Cancer Center at All Saints Healthcare
Racine, Wisconsin, United States
Site recruitment: Not reported
Saint John Regional Hospital
Saint John, New Brunswick, Canada
Site recruitment: Not reported
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

ClinicalTrials.gov · NCT02064582 · Registry updated: 2020-10-12

Condition / research focus: Prostate Cancer
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2014-05. Completion: 2018-06-09 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Enzalutamide (drug) — also listed as: Xtandi
Leuprolide acetate (drug) — also listed as: Lupron
radiation (radiation)

Where the study takes place — 1 listed sites

UT Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

ClinicalTrials.gov · NCT02472275 · Registry updated: 2020-10-06

Condition / research focus: Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
Sponsor: Barbara Ann Karmanos Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2015-06. Completion: 2019-08-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Antiandrogen Therapy (drug) — also listed as: ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy
Laboratory Biomarker Analysis (other)
Multitargeted Tyrosine Kinase Inhibitor PLX3397 (drug) — also listed as: PLX3397
Radiation Therapy (radiation) — also listed as: Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

Where the study takes place — 3 listed sites

Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Site recruitment: Not reported
Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology
Petoskey, Michigan, United States
Site recruitment: Not reported
Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology
Petoskey, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

ClinicalTrials.gov · NCT02059213 · Registry updated: 2020-09-16

Condition / research focus: Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2014-06. Completion: 2019-06-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ibrance (drug) — also listed as: PD 0332991, Palbociclib
Bicalutamide (drug) — also listed as: Casodex
Zoladex (drug) — also listed as: Goserelin acetate implant
Lupron Depot (drug) — also listed as: Leuprolide

Where the study takes place — 8 listed sites

City of Hope Cancer Center
Duarte, California, United States
Site recruitment: Not reported
Northwestern University
Chicago, Illinois, United States
Site recruitment: Not reported
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Site recruitment: Not reported
University of Michigan Hospital
Ann Arbor, Michigan, United States
Site recruitment: Not reported
Washington University in St. Louis
St Louis, Missouri, United States
Site recruitment: Not reported
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Site recruitment: Not reported
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:51 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Phase 3CompletedINTERVENTIONAL

Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer

ClinicalTrials.gov · NCT00003653 · Registry updated: 2021-06-23

Condition / research focus: Prostate Cancer
Sponsor: NCIC Clinical Trials Group
Countries with listed sites: Canada
Registry dates and results: Start: 1999-01-05. Completion: 2013-01-10 (may be estimated). No results posted in this registry response.

Products and interventions (7)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bicalutamide (drug)
buserelin (drug)
cyproterone acetate (drug)
flutamide (drug)
goserelin (drug)
leuprolide acetate (drug)
nilutamide (drug)

Where the study takes place — 29 listed sites

Tom Baker Cancer Centre
Calgary, Alberta, Canada
Site recruitment: Not reported
Cross Cancer Institute
Edmonton, Alberta, Canada
Site recruitment: Not reported
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, Canada
Site recruitment: Not reported
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, Canada
Site recruitment: Not reported
Clinical Research Unit at Vancouver Coastal
Vancouver, British Columbia, Canada
Site recruitment: Not reported
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada
Site recruitment: Not reported
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Site recruitment: Not reported
The Vitalite Health Network - Dr. Leon Richard
Moncton, New Brunswick, Canada
Site recruitment: Not reported
Atlantic Health Sciences Corporation
Saint John, New Brunswick, Canada
Site recruitment: Not reported
Dr. H. Bliss Murphy Cancer Centre
St. John's, Newfoundland and Labrador, Canada
Site recruitment: Not reported
QEII Health Sciences Center
Halifax, Nova Scotia, Canada
Site recruitment: Not reported
William Osler Health Centre, Brampton Memorial
Brampton, Ontario, Canada
Site recruitment: Not reported
Northeast Cancer Center Health Sciences
Greater Sudbury, Ontario, Canada
Site recruitment: Not reported
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
Site recruitment: Not reported
Cancer Centre of Southeastern Ontario at Kingston
Kingston, Ontario, Canada
Site recruitment: Not reported
London Regional Cancer Program
London, Ontario, Canada
Site recruitment: Not reported
Credit Valley Hospital
Mississauga, Ontario, Canada
Site recruitment: Not reported
Ottawa Health Research Institute - General Division
Ottawa, Ontario, Canada
Site recruitment: Not reported
Niagara Health System
St. Catharines, Ontario, Canada
Site recruitment: Not reported
Thunder Bay Regional Health Science Centre
Thunder Bay, Ontario, Canada
Site recruitment: Not reported
Odette Cancer Centre
Toronto, Ontario, Canada
Site recruitment: Not reported
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Site recruitment: Not reported
Windsor Regional Cancer Centre
Windsor, Ontario, Canada
Site recruitment: Not reported
CHUM - Hopital Notre-Dame
Montreal, Quebec, Canada
Site recruitment: Not reported
McGill University - Dept. Oncology
Montreal, Quebec, Canada
Site recruitment: Not reported
CHUQ-Pavillon Hotel-Dieu de Quebec
Québec, Quebec, Canada
Site recruitment: Not reported
Centre hospitalier universitaire de Sherbrooke
Sherbrooke, Quebec, Canada
Site recruitment: Not reported
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Site recruitment: Not reported
Saskatoon Cancer Centre
Saskatoon, Saskatchewan, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2

ClinicalTrials.gov · NCT02229734 · Registry updated: 2021-06-04

Condition / research focus: Prostate Cancer
Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Countries with listed sites: Canada
Registry dates and results: Start: 2014-12. Completion: 2021-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Radiation (radiation)
Androgen Suppression (drug) — also listed as: LHRH agonist

Where the study takes place — 1 listed sites

London Regional Cancer Program of the Lawson Health Research Institute
London, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Efficacy and Safety of Leuprorelin 3M in Premenopausal Women With Hormone Receptor-positive Breast Cancer

ClinicalTrials.gov · NCT04891731 · Registry updated: 2021-05-18

Condition / research focus: Hormone Receptor-positive Breast Cancer
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-05. Completion: 2023-09 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

AI or TAM (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Not applicableNot yet recruitingINTERVENTIONAL

Surgery and ART For Endometrioma

ClinicalTrials.gov · NCT03717870 · Registry updated: 2021-04-29

Condition / research focus: Ovarian Endometrioma; Infertility, Female
Sponsor: Università degli Studi dell'Insubria
Countries with listed sites: No country reported
Registry dates and results: Start: 2023-10. Completion: 2027-10 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Laparoscopic enucleation of ovarian endometrioma. (procedure)
Prolonged pituitary downregulation (procedure)
Assisted Reproductive Technology (ART) (procedure)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

The Safety and Pharmacokinetic/Pharmacodynamic Study of CKD-841 in Postmenopausal Female, Phase 1

ClinicalTrials.gov · NCT04840745 · Registry updated: 2021-04-19

Condition / research focus: Early Puberty
Sponsor: Chong Kun Dang Pharmaceutical
Countries with listed sites: South Korea
Registry dates and results: Start: 2021-04. Completion: 2021-11 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

CKD-841 A-1 3.75mg (drug) — also listed as: CKD-841
CKD-841 A-1 1.88mg (drug) — also listed as: CKD-841
CKD-841 D 2.92mg (drug) — also listed as: CKD-841
Leuplin Inj. 3.75 mg (drug) — also listed as: Leuplin.Inj

Where the study takes place — 1 listed sites

Severance Hospital
Seoul, Yonsei-ro, Seodaemun-gu 50-1, South Korea
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

Cytoreductive Prostatectomy in Treating Patients With Newly Diagnosed, Metastatic Prostate Cancer

ClinicalTrials.gov · NCT02458716 · Registry updated: 2021-04-08

Condition / research focus: Metastatic Prostate Carcinoma; Metastatic Prostatic Adenocarcinoma; Prostate Carcinoma Metastatic to the Bone
Sponsor: Rutgers, The State University of New Jersey
Countries with listed sites: United States
Registry dates and results: Start: 2015-03-06. Completion: 2020-01-14 (may be estimated). No results posted in this registry response.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Robotic Assisted Radical Prostatectomy (procedure)
Conventional open retropubic radical prostectomy (procedure)
Laboratory Biomarker Analysis (other)
Quality-of-Life Assessment (other) — also listed as: Quality of Life Assessment
ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide) (drug) — also listed as: Hormone therapy

Where the study takes place — 3 listed sites

City of Hope National Medical Center (COH)
Duarte, California, United States
Site recruitment: Not reported
University of California, Irvine (UCI)
Orange, California, United States
Site recruitment: Not reported
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2RecruitingINTERVENTIONAL

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

ClinicalTrials.gov · NCT03541928 · Registry updated: 2021-04-06

Condition / research focus: High-risk Prostate Cancer; Prostate Cancer
Sponsor: The Methodist Hospital Research Institute
Countries with listed sites: United States
Registry dates and results: Start: 2018-08-02. Completion: 2023-07 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

HSV-Tk (drug) — also listed as: Gene therapy, AdV-tk gene therapy, Herpes simplex virus thymidine kinase
Valacyclovir (drug) — also listed as: Valtrex
Bicalutamide (drug) — also listed as: Casodex
Leuprolide Acetate (drug) — also listed as: Lupron
Brachytherapy, External beam radiotherapy (radiation) — also listed as: HDR, EBRT
Radical prostatectomy (procedure) — also listed as: Prostatectomy

Where the study takes place — 1 listed sites

Houston Methodist Hospital
Houston, Texas, United States
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

ClinicalTrials.gov · NCT01338987 · Registry updated: 2021-03-18

Condition / research focus: Myelodysplastic Syndrome; Acute Lymphocytic Leukemia; Acute Myelogenous Leukemia; Chronic Myelogenous Leukemia; Chronic Myelomonocytic Leukemia
Sponsor: National Cancer Institute (NCI)
Countries with listed sites: United States
Registry dates and results: Start: 2011-04-19. Completion: 2020-11-19 (may be estimated). Results are posted in this registry.

Products and interventions (10)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

First Allogeneic Bone Marrow Transplant (BMT) (procedure)
Leuprolide (drug) — also listed as: Lupron
18F FLT (drug) — also listed as: [18F]fluorothymidine
Cyclophosphamide (drug) — also listed as: Cytoxan
Methotrexate (drug) — also listed as: Trexall
Tacrolimus (drug) — also listed as: Prograf
Total Body Irradiation (radiation)
Busulfan (drug) — also listed as: Busulfex
Fludarabine (drug) — also listed as: Fludara
Second Allogeneic Bone Marrow Transplantation (procedure)

Where the study takes place — 3 listed sites

Childrens National Medical Center
Washington D.C., District of Columbia, United States
Site recruitment: Not reported
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
Site recruitment: Not reported
University of Oklahoma
Oklahoma City, Oklahoma, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1UnknownINTERVENTIONAL

To Compare the Safety and Pharmacokinetics of PT105 With PT105R in Healthy Postmenopausal Female Volunteers

ClinicalTrials.gov · NCT04783636 · Registry updated: 2021-03-17

Condition / research focus: Prostate Cancer
Sponsor: Peptron, Inc.
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-03-11. Completion: 2021-07-20 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

leuprorelin acetate 3.75mg (drug) — also listed as: PT105

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Modified Downregulation for Women With Adenomyosis of the Uterus Prior to Frozen-thawed Embryo Transfer.

ClinicalTrials.gov · NCT03946722 · Registry updated: 2021-02-16

Condition / research focus: Adenomyosis
Sponsor: University College, London
Countries with listed sites: United Kingdom
Registry dates and results: Start: 2020-08-17. Completion: 2024-05-17 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

GnRH analogue downregulation (drug)
Participant questionnaire (other)

Where the study takes place — 1 listed sites

University College London Hospital
London, United Kingdom
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase 4UnknownINTERVENTIONAL

Psychological Impact of Amenorrhea in Women With Endometriosis

ClinicalTrials.gov · NCT02393482 · Registry updated: 2021-02-04

Condition / research focus: Amenorrhea; Endometriosis; Quality of Life
Sponsor: University of Cagliari
Countries with listed sites: Italy
Registry dates and results: Start: 2021-06. Completion: 2022-06 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Estroprogestinic therapy (Etinil-estradiol/levonorgestre) (drug)
Gonadotropin-releasing hormone agonist (Leuprorelin acetate) (drug)
Add back therapy 1 (tibolone) (drug)
Add back therapy 2 (calcium carbonate/colecalciferol) (drug)

Where the study takes place — 1 listed sites

University of Cagliari,Obstetrics and Gynecological Department,
Monserrato, Cagliari, Italy
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2WithdrawnINTERVENTIONAL

Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study

ClinicalTrials.gov · NCT04585932 · Registry updated: 2021-01-20

Condition / research focus: Biochemically Recurrent Prostate Carcinoma; Metastatic Prostate Carcinoma; Oligometastatic Prostate Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
Sponsor: M.D. Anderson Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2020-11-24. Completion: 2021-01-08 (may be estimated). No results posted in this registry response.

Products and interventions (6)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Apalutamide (drug) — also listed as: ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927
Degarelix (drug) — also listed as: FE200486, Firmagon
Leuprolide Acetate (drug) — also listed as: A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur
Quality-of-Life Assessment (other) — also listed as: Quality of Life Assessment
Questionnaire Administration (other)
Radiation Therapy (radiation) — also listed as: Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

Where the study takes place — 1 listed sites

M D Anderson Cancer Center
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome

ClinicalTrials.gov · NCT04622761 · Registry updated: 2021-01-05

Condition / research focus: Prostate Cancer
Sponsor: The Clatterbridge Cancer Centre NHS Foundation Trust
Countries with listed sites: No country reported
Registry dates and results: Start: 2021-01-15. Completion: 2026-05-02 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Cabazitaxel (drug) — also listed as: jevtana, XRP6258, RPR116258A

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

ClinicalTrials.gov · NCT03931915 · Registry updated: 2020-12-11

Condition / research focus: Endometriosis
Sponsor: ASKA Pharmaceutical Co., Ltd.
Countries with listed sites: Japan
Registry dates and results: Start: 2019-05-08. Completion: 2020-09-28 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

TAK-385 (drug) — also listed as: relugolix
Leuprorelin acetate (drug)

Where the study takes place — 41 listed sites

Chubu Rosai Hospital
Aichi, Japan
Site recruitment: Not reported
Meitetsu Hospital
Aichi, Japan
Site recruitment: Not reported
Aiiku Ladies Clinic
Chiba, Japan
Site recruitment: Not reported
Chiba Aoba Municipal Hospital
Chiba, Japan
Site recruitment: Not reported
Tokyo Bay Urayasu Ichikawa Medical Center
Chiba, Japan
Site recruitment: Not reported
Tsujinaka Hospital Kashiwanoha
Chiba, Japan
Site recruitment: Not reported
Fujito Clinic
Hiroshima, Japan
Site recruitment: Not reported
Hashimoto Clinic
Hokkaido, Japan
Site recruitment: Not reported
Tokeidai Memorial Hospital
Hokkaido, Japan
Site recruitment: Not reported
Yoshio Obstetrics Gynecology Hospital
Hokkaido, Japan
Site recruitment: Not reported
Shinsuma Hospital
Hyōgo, Japan
Site recruitment: Not reported
Kagawa Prefectural Central Hospital
Kagawa, Japan
Site recruitment: Not reported
Takamatsu Red Cross Hospital
Kagawa, Japan
Site recruitment: Not reported
Fujisawa City Hospital
Kanagawa, Japan
Site recruitment: Not reported
Rinkan Clinic
Kanagawa, Japan
Site recruitment: Not reported
Second Kawasaki Saiwai Clinic
Kanagawa, Japan
Site recruitment: Not reported
Tawada Ladies Clinic
Kanagawa, Japan
Site recruitment: Not reported
Japanese Red Cross Kumamoto Hospital
Kumamoto, Japan
Site recruitment: Not reported
Kurashiki Medical Clinic
Okayama, Japan
Site recruitment: Not reported
Chayamachi Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Hayakawa Clinic
Osaka, Japan
Site recruitment: Not reported
Minami-Morimachi Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Nomura Clinic Nanba
Osaka, Japan
Site recruitment: Not reported
Rikako Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Tanabe Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Yoshimura Ladies Clinic
Osaka, Japan
Site recruitment: Not reported
Dantsuka Clinic
Saitama, Japan
Site recruitment: Not reported
Kashiwazaki Ladies Clinic
Saitama, Japan
Site recruitment: Not reported
Maruyama Memorial General Hospital
Saitama, Japan
Site recruitment: Not reported
Kusatsu General Hospital
Shiga, Japan
Site recruitment: Not reported
Akasaka-Mitsuke Miyazaki Clinic
Tokyo, Japan
Site recruitment: Not reported
Ginza Yoshida Hospital
Tokyo, Japan
Site recruitment: Not reported
Hamada Hospital
Tokyo, Japan
Site recruitment: Not reported
Ikebukuro Metroporitan Clinic
Tokyo, Japan
Site recruitment: Not reported
NS Clinic
Tokyo, Japan
Site recruitment: Not reported
Sei Women's Clinic
Tokyo, Japan
Site recruitment: Not reported
Seijo Kinoshita Hospital
Tokyo, Japan
Site recruitment: Not reported
Shimamura Memorial Hospital
Tokyo, Japan
Site recruitment: Not reported
Toranomon Women's Clinic
Tokyo, Japan
Site recruitment: Not reported
Yokokura Clinic
Tokyo, Japan
Site recruitment: Not reported
Yukawa Women's Clinic
Tokyo, Japan
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

ClinicalTrials.gov · NCT00970203 · Registry updated: 2020-11-03

Condition / research focus: Cancer of Prostate; Cancer of the Prostate; Neoplasms, Prostate; Neoplasms, Prostatic; Prostate Cancer; Prostate Neoplasms; Prostatic Cancer
Sponsor: Roswell Park Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2009-09. Completion: 2019-10-05 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

androgen ablation (AA) (biological)
DC1 vaccine (biological) — also listed as: alpha dendritic cell 1 vaccine

Where the study takes place — 1 listed sites

University of Pittsburgh Cancer institute
Pittsburgh, Pennsylvania, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Growth Hormone and GnRH Agonist in Adolescents With Acquired Hypothyroidism

ClinicalTrials.gov · NCT00206375 · Registry updated: 2020-10-30

Condition / research focus: Hypothyroidism
Sponsor: Baylor College of Medicine
Countries with listed sites: United States
Registry dates and results: Start: 2003-05. Completion: 2011-11 (may be estimated). Results are posted in this registry.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Growth hormone (drug) — also listed as: Humatrope
Growth hormone treatment and puberty (drug) — also listed as: Humatrope

Where the study takes place — 1 listed sites

Baylor college of Medicine
Houston, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3CompletedINTERVENTIONAL

Hormone Therapy Plus Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Prostate Cancer

ClinicalTrials.gov · NCT00004054 · Registry updated: 2020-10-22

Condition / research focus: Prostate Cancer
Sponsor: Radiation Therapy Oncology Group
Countries with listed sites: Canada · United States
Registry dates and results: Start: 2000-01. Completion: 2013-11 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

bicalutamide (drug) — also listed as: Casodex
estramustine phosphate sodium (drug)
etoposide (drug)
flutamide (drug) — also listed as: Eulexin
paclitaxel (drug)
Luteinizing hormone releasing hormone [LHRH] agonist (drug)
Radiation therapy (radiation)
warfarin (drug) — also listed as: Coumadin

Where the study takes place — 54 listed sites

University of Alabama at Birmingham Comprehensive Cancer Center
Birmingham, Alabama, United States
Site recruitment: Not reported
Foundation for Cancer Research and Education
Phoenix, Arizona, United States
Site recruitment: Not reported
Mount Diablo Medical Center
Concord, California, United States
Site recruitment: Not reported
Sutter Health Western Division Cancer Research Group
Greenbrae, California, United States
Site recruitment: Not reported
CCOP - Santa Rosa Memorial Hospital
Santa Rosa, California, United States
Site recruitment: Not reported
University of Colorado Cancer Center at University of Colorado Health Sciences Center
Denver, Colorado, United States
Site recruitment: Not reported
Baptist Hospital of Miami
Miami, Florida, United States
Site recruitment: Not reported
Lutheran General Cancer Care Center
Park Ridge, Illinois, United States
Site recruitment: Not reported
Methodist Cancer Center at Methodist Hospital
Indianapolis, Indiana, United States
Site recruitment: Not reported
Ball Memorial Hospital Cancer Center
Muncie, Indiana, United States
Site recruitment: Not reported
Markey Cancer Center at University of Kentucky Chandler Medical Center
Lexington, Kentucky, United States
Site recruitment: Not reported
Mary Bird Perkins Cancer Center
Baton Rouge, Louisiana, United States
Site recruitment: Not reported
CCOP - Ochsner
New Orleans, Louisiana, United States
Site recruitment: Not reported
Anne Arundel Oncology Center
Annapolis, Maryland, United States
Site recruitment: Not reported
Greater Baltimore Medical Center and Cancer Center
Baltimore, Maryland, United States
Site recruitment: Not reported
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
Site recruitment: Not reported
West Michigan Cancer Center
Kalamazoo, Michigan, United States
Site recruitment: Not reported
Marquette General Hospital
Marquette, Michigan, United States
Site recruitment: Not reported
CCOP - Metro-Minnesota
Saint Louis Park, Minnesota, United States
Site recruitment: Not reported
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, United States
Site recruitment: Not reported
CCOP - Southern Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Site recruitment: Not reported
Veterans Affairs Medical Center - East Orange
East Orange, New Jersey, United States
Site recruitment: Not reported
Monmouth Medical Center
Long Branch, New Jersey, United States
Site recruitment: Not reported
South Jersey Regional Cancer Center
Millville, New Jersey, United States
Site recruitment: Not reported
Atlantic City Medical Center
Pomona, New Jersey, United States
Site recruitment: Not reported
Fox Chase Cancer Center at St. Francis Medical Center
Trenton, New Jersey, United States
Site recruitment: Not reported
CCOP - North Shore University Hospital
Manhasset, New York, United States
Site recruitment: Not reported
Herbert Irving Comprehensive Cancer Center at Columbia University
New York, New York, United States
Site recruitment: Not reported
Akron General Medical Center
Akron, Ohio, United States
Site recruitment: Not reported
Akron City Hospital
Akron, Ohio, United States
Site recruitment: Not reported
CCOP - Columbus
Columbus, Ohio, United States
Site recruitment: Not reported
Arthur G. James Cancer Hospital - Ohio State University
Columbus, Ohio, United States
Site recruitment: Not reported
CCOP - Dayton
Dayton, Ohio, United States
Site recruitment: Not reported
CCOP - Toledo Community Hospital
Toledo, Ohio, United States
Site recruitment: Not reported
John and Dorothy Morgan Cancer Center at Lehigh Valley Hospital
Allentown, Pennsylvania, United States
Site recruitment: Not reported
St. Luke's Hospital Cancer Center
Bethlehem, Pennsylvania, United States
Site recruitment: Not reported
Delaware County Memorial Hospital
Drexel Hill, Pennsylvania, United States
Site recruitment: Not reported
Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Fox Chase Cancer Center
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Albert Einstein Cancer Center
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
CCOP - MainLine Health
Wynnewood, Pennsylvania, United States
Site recruitment: Not reported
Wellspan Health - York Cancer Center
York, Pennsylvania, United States
Site recruitment: Not reported
University of Texas - MD Anderson Cancer Center
Houston, Texas, United States
Site recruitment: Not reported
LDS Hospital
Salt Lake City, Utah, United States
Site recruitment: Not reported
Dixie Regional Medical Center
St. George, Utah, United States
Site recruitment: Not reported
University Cancer Center at University of Washington Medical Center
Seattle, Washington, United States
Site recruitment: Not reported
CCOP - St. Vincent Hospital Cancer Center, Green Bay
Green Bay, Wisconsin, United States
Site recruitment: Not reported
St. Vincent Hospital
Green Bay, Wisconsin, United States
Site recruitment: Not reported
Gundersen Lutheran Cancer Center at Gundersen Lutheran Medical Center
La Crosse, Wisconsin, United States
Site recruitment: Not reported
St. Luke's Medical Center
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States
Site recruitment: Not reported
All Saints Cancer Center at All Saints Healthcare
Racine, Wisconsin, United States
Site recruitment: Not reported
Saint John Regional Hospital
Saint John, New Brunswick, Canada
Site recruitment: Not reported
Cancer Care Ontario-London Regional Cancer Centre
London, Ontario, Canada
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer

ClinicalTrials.gov · NCT02064582 · Registry updated: 2020-10-12

Condition / research focus: Prostate Cancer
Sponsor: University of Texas Southwestern Medical Center
Countries with listed sites: United States
Registry dates and results: Start: 2014-05. Completion: 2018-06-09 (may be estimated). Results are posted in this registry.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Enzalutamide (drug) — also listed as: Xtandi
Leuprolide acetate (drug) — also listed as: Lupron
radiation (radiation)

Where the study takes place — 1 listed sites

UT Southwestern Medical Center
Dallas, Texas, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 1CompletedINTERVENTIONAL

PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate Cancer

ClinicalTrials.gov · NCT02472275 · Registry updated: 2020-10-06

Condition / research focus: Stage I Prostate Adenocarcinoma; Stage II Prostate Adenocarcinoma; Stage III Prostate Adenocarcinoma
Sponsor: Barbara Ann Karmanos Cancer Institute
Countries with listed sites: United States
Registry dates and results: Start: 2015-06. Completion: 2019-08-05 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Antiandrogen Therapy (drug) — also listed as: ADT, Androgen Deprivation Therapy, Anti-androgen Therapy, Anti-androgen Treatment, Antiandrogen Treatment, Hormone Deprivation Therapy, Hormone-Deprivation Therapy
Laboratory Biomarker Analysis (other)
Multitargeted Tyrosine Kinase Inhibitor PLX3397 (drug) — also listed as: PLX3397
Radiation Therapy (radiation) — also listed as: Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation

Where the study takes place — 3 listed sites

Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
Site recruitment: Not reported
Karmanos Cancer Institute at McLaren Northern Michigan - Petoskey Radiation Oncology
Petoskey, Michigan, United States
Site recruitment: Not reported
Karmanos Cancer Institute at McLaren Northern Michigan- Petoskey Medical Oncology
Petoskey, Michigan, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

ClinicalTrials.gov · NCT02059213 · Registry updated: 2020-09-16

Condition / research focus: Prostate Cancer
Sponsor: University of Michigan Rogel Cancer Center
Countries with listed sites: United States
Registry dates and results: Start: 2014-06. Completion: 2019-06-04 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Ibrance (drug) — also listed as: PD 0332991, Palbociclib
Bicalutamide (drug) — also listed as: Casodex
Zoladex (drug) — also listed as: Goserelin acetate implant
Lupron Depot (drug) — also listed as: Leuprolide

Where the study takes place — 8 listed sites

City of Hope Cancer Center
Duarte, California, United States
Site recruitment: Not reported
Northwestern University
Chicago, Illinois, United States
Site recruitment: Not reported
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Site recruitment: Not reported
University of Michigan Hospital
Ann Arbor, Michigan, United States
Site recruitment: Not reported
Washington University in St. Louis
St Louis, Missouri, United States
Site recruitment: Not reported
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Site recruitment: Not reported
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
Site recruitment: Not reported
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →